Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone protection in older critically ill ICU survivors
ACTRN12621000085875Phase 2Active, not recruiting
- Sponsor
- Monash University
- Start
- Jul 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Denosumab, Zoledronic acid and Placebo (3 arms). Primary endpoint: Annualised change in femoral neck bone mineral density. Started Jul 2021; status: active, not recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12621000085875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000085875.